Gold Partners

Cantor Colburn, the fastest growing patent law firm in the United States over the last 10 years (Juristat) and the 3rd largest patent law firm (IP Law360), offers a full range of intellectual property services to clients around the world. Our pharmaceutical and life sciences attorneys handle litigation, patent prosecution, inter partes reviews and other Patent Office review proceedings, opinions, landscapes, competitive intelligence, licensing and other transactional services, portfolio management and more. Cantor Colburn is the #1 law firm for handling Mayo/Myriad rejections (Juristat). Our attorneys have extensive experience in a wide variety of pharmaceutical and life science technologies, including chemistry, biochemistry, organic chemistry and pharmaceuticals. Cantor Colburn has substantial experience representing clients in Hatch-Waxman and related pharmaceutical litigation matters. We focus on securing intellectual property rights for drug discovery companies seeking to protect the early stage technology, as well as defending generic pharmaceutical companies against allegations of patent infringement, including those that arise out of ANDA filings. Cantor Colburn counsels its pharmaceutical clients even before suit is filed, providing guidance during the preparation of ANDAs, performing opinion work, and preparing Paragraph IV letters.
Ranked among the top 100 law firms in the country, Cozen O’Connor has more than 700 attorneys in 26 cities across two continents. We are a full-service firm with nationally recognized practices in litigation, business law, and government relations, and our attorneys have experience operating in all sectors of the economy. Cozen O’Connor’s dedicated Hatch-Waxman & Biologics team are seasoned trial lawyers who also have advanced scientific degrees and industry experience in fields including organic chemistry, molecular cell biology and biophysics. Our team has handled more than 70 Hatch-Waxman matters in the last five years. Moreover, our team is the first to try a case under the BPCIA, obtaining a verdict of non-infringement for the biosimilar applicant. We then obtained a unanimous decision from the Federal Circuit affirming the district court’s non-infringement judgment.
Green Griffith focuses exclusively on IP issues involving pharmaceuticals, chemistry and biotechnology—specializing in litigation. Our attorneys share decades of litigation experience assisting both generics and brand companies navigate the Hatch-Waxman Act. As stated in AIM Patent 1000 (2017): “Green, Griffith is a uniquely talented and experienced intellectual property firm that has been making serious waves in the biopharmaceutical market. As for the Green, Griffith modus operandi, they are tirelessly committed to helping their clients succeed; collaborating with their clients as strategic partners – albeit partners who happen to be excellent at litigation.”
Acknowledged leaders in our field, we partner with our clients to provide strategic formulation development and litigation counseling concerning IP and FDA exclusivity issues affecting 505(b)(1), 505(b)(2) and ANDA applications. Pre-litigation, we provide strategies and opinions on API and excipient selection, trade dress, formulation attributes and labeling. Our trial attorneys—who have hard science backgrounds in chemistry, biology and/or biotechnology—then work with each client to execute the desired strategy—whether this involves litigation in the federal courts or IPR practice before the PTAB.

Silver Partners


Xact Data Discovery (XDD) is a leading international provider of eDiscovery, data management and managed review services for law firms and corporations. XDD helps clients optimize their eDiscovery matters by orchestrating precision communication between people, processes, technology and data. XDD has 16 offices throughout the United States and two locations in India. XDD offers exceptional customer service with a commitment to responsive, transparent and timely communication to ensure clients remain informed throughout the entire discovery life cycle.

Goldberg Segalla is one of the largest and fastest-growing law firms headquartered in the United States, with a footprint that reaches from Los Angeles to London. Its more than 400 attorneys serve regional, national, and international clients from over 20 offices, with teams based in New York, Chicago, Philadelphia, Miami, and other major business and economic centers across 10 states. An AmLaw200 firm, Goldberg Segalla handles all forms of dispute resolution, patent litigation, and complex transactions, and provides proactive legal and regulatory counsel to help companies and professionals from a wide range of industries minimize and manage risk.

Lanyard Partners


RMMS consists of over 30 attorneys focused exclusively on life sciences patent and regulatory counseling, patent litigation under Hatch-Waxman and the BPCIA, as well as post-grant review before the PTAB. RMMS attorneys embrace the science of a case, and have made it an integral part of our strategy in the over 300 pharmaceutical litigation matters clients have entrusted to us.

We understand that patent litigation is rarely an end-game, and that business decisions made throughout the product development, regulatory review, litigation, and commercialization process are equally critical to the company’s strategic plans involving any one product or a product portfolio.